The pharmaceutical industry is abuzz with news of a potential breakthrough in the treatment of Alzheimer’s disease. Eli Lilly & Co. recently announced that its experimental drug, donanemab, showed promising results in slowing the progression of the disease in a final-stage trial. This news sent the company’s shares soaring in early US trading.
However, there was a twist in the tale when the Food and Drug Administration (FDA) unexpectedly pushed back its approval decision deadline for donanemab. The agency plans to convene a last-minute meeting of its outside advisors to further review the treatment’s safety and efficacy in the late-stage trial. This meeting will likely delay any potential approval beyond the expected timeline.
This setback comes as Eli Lilly strives to compete with other pharmaceutical companies like Biogen and Eisai, whose Alzheimer’s treatment Leqembi was approved last year. Both Leqembi and donanemab are monoclonal antibodies that target the build-up of amyloid plaque in the brain, a key component of Alzheimer’s disease.
Despite the delay, Eli Lilly remains confident in the potential benefits of donanemab for people with early symptomatic Alzheimer’s. The company is committed to working with the FDA and stakeholders to address any questions or concerns that may arise.
The FDA’s decision to call for an advisory meeting underscores the high stakes involved in developing treatments for Alzheimer’s, a disease that currently affects over 6 million Americans with no cure in sight. While the agency typically follows the recommendations of its advisors, the approval of previous Alzheimer’s drugs like Aduhelm has shown that it is not bound by their advice.
In conclusion, the road to approval for donanemab may be longer than anticipated, but the potential benefits for Alzheimer’s patients could be significant. Stay tuned for further updates on this developing story in the pharmaceutical world.
Source link
